Aprea Therapeutics (APRE) Competitors $3.35 +0.05 (+1.52%) (As of 11/14/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends APRE vs. SPRO, QNCX, ATRA, VIRI, VOR, IOBT, DTIL, ALVR, ALGS, and OMGAShould you be buying Aprea Therapeutics stock or one of its competitors? The main competitors of Aprea Therapeutics include Spero Therapeutics (SPRO), Quince Therapeutics (QNCX), Atara Biotherapeutics (ATRA), Virios Therapeutics (VIRI), Vor Biopharma (VOR), IO Biotech (IOBT), Precision BioSciences (DTIL), AlloVir (ALVR), Aligos Therapeutics (ALGS), and Omega Therapeutics (OMGA). These companies are all part of the "pharmaceutical products" industry. Aprea Therapeutics vs. Spero Therapeutics Quince Therapeutics Atara Biotherapeutics Virios Therapeutics Vor Biopharma IO Biotech Precision BioSciences AlloVir Aligos Therapeutics Omega Therapeutics Aprea Therapeutics (NASDAQ:APRE) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment, community ranking and analyst recommendations. Which has more volatility & risk, APRE or SPRO? Aprea Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500. Comparatively, Spero Therapeutics has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500. Do analysts recommend APRE or SPRO? Aprea Therapeutics currently has a consensus price target of $15.50, indicating a potential upside of 362.69%. Spero Therapeutics has a consensus price target of $5.00, indicating a potential upside of 300.00%. Given Aprea Therapeutics' higher probable upside, research analysts plainly believe Aprea Therapeutics is more favorable than Spero Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aprea Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Spero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation and earnings, APRE or SPRO? Spero Therapeutics has higher revenue and earnings than Aprea Therapeutics. Aprea Therapeutics is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAprea Therapeutics$580K31.36-$14.29M-$2.81-1.19Spero Therapeutics$105.43M0.64$22.81M$0.333.79 Do insiders & institutionals have more ownership in APRE or SPRO? 34.2% of Aprea Therapeutics shares are held by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are held by institutional investors. 12.8% of Aprea Therapeutics shares are held by insiders. Comparatively, 4.5% of Spero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the MarketBeat Community believe in APRE or SPRO? Spero Therapeutics received 154 more outperform votes than Aprea Therapeutics when rated by MarketBeat users. Likewise, 69.83% of users gave Spero Therapeutics an outperform vote while only 55.32% of users gave Aprea Therapeutics an outperform vote. CompanyUnderperformOutperformAprea TherapeuticsOutperform Votes5255.32% Underperform Votes4244.68% Spero TherapeuticsOutperform Votes20669.83% Underperform Votes8930.17% Does the media refer more to APRE or SPRO? In the previous week, Aprea Therapeutics had 2 more articles in the media than Spero Therapeutics. MarketBeat recorded 8 mentions for Aprea Therapeutics and 6 mentions for Spero Therapeutics. Aprea Therapeutics' average media sentiment score of 0.52 beat Spero Therapeutics' score of 0.41 indicating that Aprea Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aprea Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spero Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is APRE or SPRO more profitable? Spero Therapeutics has a net margin of 14.74% compared to Aprea Therapeutics' net margin of -1,029.50%. Spero Therapeutics' return on equity of 25.67% beat Aprea Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aprea Therapeutics-1,029.50% -57.86% -47.94% Spero Therapeutics 14.74%25.67%14.26% SummarySpero Therapeutics beats Aprea Therapeutics on 10 of the 17 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Aprea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APRE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APRE vs. The Competition Export to ExcelMetricAprea TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.19M$7.06B$5.39B$8.88BDividend YieldN/A8.03%4.98%4.04%P/E Ratio-1.1911.53127.7817.45Price / Sales31.36348.301,250.7693.00Price / CashN/A49.2239.6536.42Price / Book0.839.086.285.86Net Income-$14.29M$154.47M$119.29M$225.23M7 Day Performance-5.63%-2.36%-1.26%-1.15%1 Month Performance8.77%3.10%2.22%3.63%1 Year Performance-15.40%36.17%35.59%24.95% Aprea Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APREAprea Therapeutics3.2589 of 5 stars$3.35+1.5%$15.50+362.7%-17.3%$18.19M$580,000.00-1.197Earnings ReportShort Interest ↑SPROSpero Therapeutics4.7576 of 5 stars$1.31-0.8%N/A+14.7%$70.73M$103.78M3.9746Short Interest ↑News CoverageQNCXQuince Therapeutics2.6439 of 5 stars$1.60-4.8%N/A+111.7%$69.25MN/A-1.2760Short Interest ↑ATRAAtara Biotherapeutics4.0054 of 5 stars$13.60+16.5%N/A+46.9%$66.78M$8.57M-0.53165Earnings ReportAnalyst ForecastNews CoverageVIRIVirios Therapeutics0.3568 of 5 stars$3.46+1.2%N/A+320.7%$66.63MN/A-12.815Gap UpVORVor Biopharma2.383 of 5 stars$0.97-2.1%N/A-53.3%$66.57MN/A-0.59140IOBTIO Biotech2.9339 of 5 stars$0.99+7.2%N/A-9.2%$65.49MN/A-0.7330Earnings ReportAnalyst ForecastShort Interest ↓Gap UpDTILPrecision BioSciences4.1704 of 5 stars$8.19-2.2%N/A-25.9%$62.82M$48.73M136.52200ALVRAlloVir1.8583 of 5 stars$0.54+0.4%N/A-65.2%$62.70MN/A-0.44110Earnings ReportShort Interest ↓ALGSAligos Therapeutics4.171 of 5 stars$19.19+7.5%N/A+31.5%$61.41M$15.53M-1.4490Short Interest ↑High Trading VolumeOMGAOmega Therapeutics2.5727 of 5 stars$1.11-3.1%N/A-46.0%$60.94M$3.09M-0.77120News CoveragePositive NewsGap Down Related Companies and Tools Related Companies SPRO Competitors QNCX Competitors ATRA Competitors VIRI Competitors VOR Competitors IOBT Competitors DTIL Competitors ALVR Competitors ALGS Competitors OMGA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:APRE) was last updated on 11/15/2024 by MarketBeat.com Staff From Our PartnersTop "Sleeping Giant" Crypto In The Market NowTop "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your fi...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredYou just voted for a financial crisisI’d like to share with you my #1 high-conviction stock to buy before Inauguration Day… and details on the asse...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aprea Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aprea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
